Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NeuroPace IncNPCE · Entity 5459 | CHIEF MEDICAL OFFICER | September 24, 2026 | September 25, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NeuroPace Inc
Report date September 24, 2026 · Filed September 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 51,357 |
Reported balance
After 2026-09-24 transaction · row 1
1 source rowRow 1 · 2026-09-24 · Tax withholding · Disposed 335 · Balance 51,357 F1: Represents the number of shares withheld by the Issuer on September 24, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares withheld by the Issuer on September 24, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 24, 2026 Filed Sep 25, 2026 20:31 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 335 | $13.97 | $4,679.95 |
DisclosureSEC source: 0001855616-26-000024 · wk-form4_1790368295.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,357 F1 · shares: Represents the number of shares withheld by the Issuer on September 24, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. F1 · price: Represents the number of shares withheld by the Issuer on September 24, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 17:03 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 358 | $14.13 | $5,058.54 |
DisclosureSEC source: 0001855616-26-000022 · wk-form4_1787950985.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,692 F1 · shares: Represents the number of shares withheld by the Issuer on August 27, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. F1 · price: Represents the number of shares withheld by the Issuer on August 27, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. Read SEC document |
| June 24, 2026 Filed Jun 25, 2026 20:12 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 335 | $16.22 | $5,433.70 |
DisclosureSEC source: 0001855616-26-000019 · wk-form4_1782418320.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,050 F1 · shares: Represents the number of shares withheld by the Issuer on June 24, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. F1 · price: Represents the number of shares withheld by the Issuer on June 24, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. Read SEC document |
| May 27, 2026 Filed May 28, 2026 20:40 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 358 | $17.06 | $6,107.48 |
DisclosureSEC source: 0001855616-26-000017 · wk-form4_1780000834.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,385 F1 · shares: Represents the number of shares withheld by the Issuer on May 27, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. F1 · price: Represents the number of shares withheld by the Issuer on May 27, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:27 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Right to Buy) · Derivative | 14,550 | $0.00 Strike: $15.36 | $0.00 |
DisclosureSEC source: 0001855616-26-000015 · wk-form4_1779222436.xml · derivative · entry 2 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,550 Underlying: Common Stock · 14,550 shares Expires 2036-05-14 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on May 15, 2027. The remaining shares subject to the option vest in thirty six (36) equal consecutive monthly installments thereafter. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:27 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 5,460 | $0.00 | $0.00 |
DisclosureSEC source: 0001855616-26-000015 · wk-form4_1779222436.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,743 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on May 15, 2027 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 24, 2026 Filed Mar 25, 2026 20:20 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 1,341 | $13.27 | $17,795.07 |
DisclosureSEC source: 0001855616-26-000011 · wk-form4_1774470047.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,283 F1 · shares: Represents the number of shares withheld by the Issuer on March 24, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. F1 · price: Represents the number of shares withheld by the Issuer on March 24, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:43 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 1,340 | $13.83 | $18,532.20 |
DisclosureSEC source: 0001855616-26-000007 · wk-form4_1772660606.xml · nonDerivative · entry 2 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,624 F3 · shares: Represents the number of shares withheld by the Issuer on March 3, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 17:51 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 358 | $14.58 | $5,219.64 |
DisclosureSEC source: 0001855616-26-000005 · wk-form4_1772473884.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,964 F1 · shares: Represents the number of shares withheld by the Issuer on February 27, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. F1 · price: Represents the number of shares withheld by the Issuer on February 27, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. Read SEC document |
| February 20, 2026 Filed Feb 23, 2026 22:31 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 3,412 | $14.34 | $48,928.08 |
DisclosureSEC source: 0001855616-26-000003 · wk-form4_1771885895.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,322 F1 · shares: Represents the number of shares withheld by the Issuer on February 20, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. F1 · price: Represents the number of shares withheld by the Issuer on February 20, 2026 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. Read SEC document |
| December 15, 2025 Filed Mar 4, 2026 21:43 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 25,000 | $15.97 | $399,250.00 |
DisclosureSEC source: 0001855616-26-000007 · wk-form4_1772660606.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,964 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.83 to $16.26, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:30 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 1,338 | $16.66 | $22,291.08 |
DisclosureSEC source: 0001855616-25-000007 · form4-12042025_041201.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,734 F1 · shares: Represents the number of shares withheld by the Issuer on December 3, 2025 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. Read SEC document |
| November 27, 2025 Filed Dec 1, 2025 21:15 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 357 | $16.50 | $5,890.50 |
DisclosureSEC source: 0001855616-25-000005 · form4-12012025_041201.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,072 F1 · shares: Represents the number of shares withheld by the Issuer on November 27, 2025 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 21:57 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 3,051 | $13.50 | $41,188.50 |
DisclosureSEC source: 0001855616-25-000003 · form4-11242025_091103.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,429 F1 · shares: Represents the number of shares withheld by the Issuer on November 20, 2025 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. Read SEC document |
| September 03, 2025 Filed Sep 5, 2025 00:24 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 1,337 | $9.36 | $12,514.32 |
DisclosureSEC source: 0001415889-25-023763 · form4-09052025_120957.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,480 F1 · shares: Represents the number of shares withheld by the Issuer on September 3, 2025 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 20:15 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 357 | $8.88 | $3,170.16 |
DisclosureSEC source: 0001415889-25-023213 · form4-08282025_040805.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,817 F1 · shares: Represents the number of shares withheld by the Issuer on August 27, 2025 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. Read SEC document |
| August 20, 2025 Filed Aug 22, 2025 20:15 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 3,052 | $8.66 | $26,430.32 |
DisclosureSEC source: 0001415889-25-022748 · form4-08222025_040801.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,174 F1 · shares: Represents the number of shares withheld by the Issuer on August 20, 2025 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award. F2 · balance_after: Includes 2,283 shares acquired pursuant to the NeuroPace, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| June 03, 2025 Filed Jun 6, 2025 23:15 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 1,338 | $13.54 | $18,116.52 |
DisclosureSEC source: 0001415889-25-016077 · form4-06062025_070601.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,943 Read SEC document |
| May 27, 2025 Filed May 29, 2025 23:10 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 357 | $12.66 | $4,519.62 |
DisclosureSEC source: 0001415889-25-014931 · form4-05292025_070503.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,281 Read SEC document |
| May 20, 2025 Filed May 21, 2025 23:15 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 3,051 | $17.99 | $54,887.49 |
DisclosureSEC source: 0001415889-25-014013 · form4-05212025_070501.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,638 Read SEC document |
| April 22, 2025 Filed Apr 23, 2025 23:44 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 237 | $10.94 | $2,592.78 |
DisclosureSEC source: 0001415889-25-011241 · form4-04232025_110434.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,689 Read SEC document |
| March 24, 2025 Filed Mar 24, 2025 22:10 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Right to Buy) · Derivative | 19,850 | $0.00 Strike: $12.30 | $0.00 |
DisclosureSEC source: 0001415889-25-008864 · form4-03242025_100346.xml · derivative · entry 2 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,850 Underlying: Common Stock · 19,850 shares Expires 2035-03-23 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on March 24, 2026. The remaining shares subject to the option vest in thirty six (36) equal consecutive monthly installments thereafter. Read SEC document |
| March 24, 2025 Filed Mar 24, 2025 22:10 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 11,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008864 · form4-03242025_100346.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,926 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on March 24, 2026 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:09 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 1,337 | $11.81 | $15,789.97 |
DisclosureSEC source: 0001415889-25-006924 · form4-03052025_090301.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,226 Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:11 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 1,430 | $12.56 | $17,960.80 |
DisclosureSEC source: 0001415889-25-006142 · form4-03032025_090340.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,563 Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 23:52 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 78,334 | $13.72 | $1,074,844.31 |
DisclosureSEC source: 0001415889-25-005577 · form4-02252025_110217.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,993 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $14.21, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form. Read SEC document |
| February 20, 2025 Filed Feb 25, 2025 23:31 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 3,405 | $14.23 | $48,453.15 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 25 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,670 Read SEC document |
| January 30, 2025 Filed Feb 1, 2025 00:16 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 200 | $15.00 | $3,000.00 |
DisclosureSEC source: 0001415889-25-002590 · form4-02012025_120253.xml · nonDerivative · entry 2 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,762 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 29, 2025 Filed Feb 1, 2025 00:16 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 100 | $15.00 | $1,500.00 |
DisclosureSEC source: 0001415889-25-002590 · form4-02012025_120253.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,962 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 24, 2025 Filed Jan 28, 2025 23:08 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 3,200 | $15.01 | $48,032.00 |
DisclosureSEC source: 0001415889-25-002207 · form4-01282025_110150.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,062 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.04, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form Read SEC document |
| January 22, 2025 Filed Feb 25, 2025 23:31 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 265 | $14.04 | $3,720.60 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 24 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,075 Read SEC document |
| December 03, 2024 Filed Feb 25, 2025 23:31 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 1,413 | $11.93 | $16,857.09 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 23 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,340 Read SEC document |
| November 20, 2024 Filed Feb 25, 2025 23:31 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 3,045 | $9.19 | $27,983.55 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 22 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,753 Read SEC document |
| October 22, 2024 Filed Feb 25, 2025 23:31 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 237 | $6.00 | $1,422.00 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 21 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,798 Read SEC document |
| September 03, 2024 Filed Feb 25, 2025 23:31 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 1,334 | $7.39 | $9,858.26 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 20 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,035 Read SEC document |
| August 20, 2024 Filed Feb 25, 2025 23:31 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 3,045 | $7.24 | $22,045.80 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 19 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,369 Read SEC document |
| July 22, 2024 Filed Feb 25, 2025 23:31 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 237 | $7.65 | $1,813.05 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 18 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,414 Read SEC document |
| June 03, 2024 Filed Feb 25, 2025 23:31 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 1,335 | $6.46 | $8,624.10 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 17 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,511 Read SEC document |
| May 20, 2024 Filed Feb 25, 2025 23:31 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 3,045 | $7.98 | $24,299.10 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 16 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,986 Read SEC document |
| April 22, 2024 Filed Feb 25, 2025 23:31 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 237 | $14.00 | $3,318.00 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 15 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,268 Read SEC document |
| March 03, 2024 Filed Feb 25, 2025 23:31 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 1,334 | $15.99 | $21,330.66 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 14 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,031 Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 01:56 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Right to Buy) · Derivative | 24,950 | $0.00 Strike: $17.11 | $0.00 |
DisclosureSEC source: 0001209191-24-004089 · doc4.xml · derivative · entry 2 Morrell Martha · CIK 0001855616 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,950 Underlying: Common Stock · 24,950 shares Expires 2034-02-26 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on February 27, 2025. The remaining shares subject to the option vest in thirty six (36) equal consecutive monthly installments thereafter. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 01:56 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-004089 · doc4.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,262 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. 25% of the RSUs vest on February 27, 2025 and the remaining RSUs vest in twelve (12) equal quarterly installments thereafter. Read SEC document |
| February 20, 2024 Filed Feb 25, 2025 23:31 UTC | NeuroPace Inc NPCE · Entity 5459 | Tax withholdingCommon Stock | 12,474 | $17.50 | $218,295.00 |
DisclosureSEC source: 0001415889-25-005571 · form4-02252025_110243.xml · nonDerivative · entry 13 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,602 Read SEC document |
| February 12, 2024 Filed Feb 25, 2025 23:51 UTC | NeuroPace Inc NPCE · Entity 5459 | Exercise / conversionStock Option (Rt to Buy) · Derivative | 50,000 | $0.00 Strike: $0.03 | $0.00 |
DisclosureSEC source: 0001415889-25-005576 · form4-02252025_110255.xml · derivative · entry 2 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,449 Underlying: Common Stock · 50,000 shares Expires 2030-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48th of the shares subject to the option vest in equal monthly installments commencing September 19, 2020. If, at the time of the initial public offering, less than 232,371 of the shares subject to this option remain unvested, an amount of shares subject to this option shall vest and become immediately exercisable immediately prior to the offering such that a total of 232,371 shares subject to this option will be vested and immediately exercisable, subject to Dr. Morrells continued service with NeuroPace, Inc. Following such acceleration, the remaining unvested shares subject to this option will continue to vest in equal monthly installments over 48 months. Read SEC document |
| February 12, 2024 Filed Feb 25, 2025 23:51 UTC | NeuroPace Inc NPCE · Entity 5459 | Exercise / conversionCommon Stock | 50,000 | $0.03 | $1,300.00 |
DisclosureSEC source: 0001415889-25-005576 · form4-02252025_110255.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 13,847 shares acquired pursuant to the NeuroPace, Inc. 2021 Employee Stock Purchase Plan between April 22, 2021 and June 7, 2024. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 00:16 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 3,446 | $15.17 | $52,278.23 |
DisclosureSEC source: 0001209191-24-002942 · doc4.xml · nonDerivative · entry 2 Morrell Martha · CIK 0001855616 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,762 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.285, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
| February 02, 2024 Filed Feb 7, 2024 00:16 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 14,143 | $15.07 | $213,122.28 |
DisclosureSEC source: 0001209191-24-002942 · doc4.xml · nonDerivative · entry 1 Morrell Martha · CIK 0001855616 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,208 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.19, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 02:47 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 663 | $15.04 | $9,971.06 |
DisclosureSEC source: 0001209191-24-002596 · doc4.xml · nonDerivative · entry 3 Morrell Martha · CIK 0001855616 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,351 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.08, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 02:47 UTC | NeuroPace Inc NPCE · Entity 5459 | SaleCommon Stock | 1,923 | $15.08 | $28,989.61 |
DisclosureSEC source: 0001209191-24-002596 · doc4.xml · nonDerivative · entry 2 Morrell Martha · CIK 0001855616 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,014 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.125, inclusive. The reporting person undertakes to provide the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.